# US 2010/0303926 A1 · Organic compounds

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0303926 A1
- Document ID: US20100303926A1
- Status: Published application
- Kind: A1
- Application number: 12/745,100
- Filed: 2008-12-04
- Published: 2010-12-02
- Earliest claimed: 2007-12-05
- Assignees: Novartis AG
- Inventors: Peter Herold; Stjepan Jelakovic; Robert Mah; Vincenzo Tschinke
- Web page: https://patentgrep.com/patent/US20100303926A1

## CPC

- C07D 413/12: linked by a chain containing hetero atoms as chain links
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/04: Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 9/12: Antihypertensives
- A61P 13/12: of the kidneys
- A61P 27/06: Antiglaucoma agents or miotics
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to compounds of the general formula (I) and the salts thereof, preferably the pharmaceutically acceptable salts thereof; in which in which R1 has the meaning explained in the description, a process for their preparation and the use of these compounds as medicines, especially as renin inhibitors.

## Claims

### Claim 1

A compound of the formula
its prodrug, its nitosated or nitrate ester derivative or its pharmaceutically acceptable salt, in which
R1 is C1-8-alkanoyloxy, C1-8-alkanoyloxy-C1-8-alkyl, C1-8-alkoxy, C1-8-alkoxy-C1-8-alkoxy, C1-8-alkoxy-C1-8-alkoxy-C1-8-alkyl, C1-8-alkoxy-C1-8-alkyl, C1-8-alkoxycarbonylamino, C1-8-alkoxycarbonylamino-C1-8-alkyl, C0-8-alkylcarbonylamino, C0-8-alkylcarbonylamino-C1-8-alkyl, O—C1-8-alkylated carboxyl, O—C1-8-alkylated carboxyl-C1-8-alkyl, optionally N-mono- or N,N-di-C1-8-alkylated amino, optionally N-mono- or N,N-di-C1-8-alkylated amino-C1-8-alkyl, optionally N-mono- or N,N-di-C1-8-alkylated amino-carbonylamino, optionally N-mono- or N,N-di-C1-8-alkylated amino-carbonylamino-C1-8-alkyl, heterocyclyl, heterocyclyl-C1-8-alkyl, heterocyclyl-C0-8-alkyl-carbonyl-C0-8-alkylamino, heterocyclyl-C0-8-alkyl-carbonyl-C0-8-alkylamino-C1-8-alkyl, heterocyclyl-C0-8-alkyl-carbonyl-C1-8-alkyl, cycloalkyl-C0-8-alkyl-carbonyl-C0-8-alkylamino, cycloalkyl-C0-8-alkyl-carbonyl-C0-8-alkylamino-C1-8-alkyl, hydroxyl, hydroxy substituted C1-8-alkyl, optionally N-mono-, -di- or -tri-C1-8-alkylated or heterocyclyl-substituted ureido, or optionally N-mono-, -di- or -tri-C1-8-alkylated or heterocyclyl-substituted ureido-C1-8-alkyl and whereby the heterocyclyl and cycloalkyl radicals mentioned hereinbefore are unsubstituted or substituted.

### Claim 2 (depends on 1)

The compound according to claim 1 in which R1 is hydroxyl or straight-chain omega-hydroxy substituted C1-4-alkyl, or a pharmaceutically acceptable salt thereof.

### Claim 3 (depends on 1)

The compound according to claim 1 in which R1 is C1-4-alkoxy, C1-4-alkoxy-C1-4-alkyl or C1-4-alkoxy-C1-4-alkoxy, or a pharmaceutically acceptable salt thereof.

### Claim 4 (depends on 1)

The compound according to claim 1 in which R1 is straight-chain C1-4-alkoxy, straight chain C1-4-alkoxy-straight-chain-C1-4-alkyl or straight-chain C1-4-alkoxy-straight-chain C1-4-alkoxy, or a pharmaceutically acceptable salt thereof.

### Claim 5 (depends on 1)

The compound according to claim 1 in which R1 is C0-3-alkylcarbonylamino or C0-3-alkylcarbonylamino-C1-4-alkyl, or a pharmaceutically acceptable salt thereof.

### Claim 6 (depends on 1)

The compound according to claim 1 in which R1 is optionally N-mono- or N,N-di-C1-4-alkylated amino or optionally N-mono- or N,N-di-C1-4-alkylated amino-C1-4-alkyl, or a pharmaceutically acceptable salt thereof.

### Claim 7 (depends on 1)

The compound according to claim 1 in which R1 is optionally substituted, N-bound saturated N-containing C5-6-heterocyclyl, or a pharmaceutically acceptable salt thereof.

### Claim 8 (depends on 1)

The compound according to claim 1 in which R1 is hydroxy, hydroxy-C1-2-alkyl, C1-2-alkoxy, 2-methoxy-ethoxy, acetyloxy, C0-2-alkylcarbonylamino, C0-2-monoalkylamino, N-bound pyrrolidinyl, N-bound piperidinyl or N-bound pyrrolidinyl-carbonyl-C1-2-alkyl, or a pharmaceutically acceptable salt thereof.

### Claim 9

The compound:
(3S,4R,5R)-4-[4-((R)-2-Ethoxy-propoxymethyl)-phenyl]-3-hydroxymethyl-5-[4-(3-methoxy-propyl)-3,4-dihydro-2H-benzo[1,4]oxazin-6-ylmethoxy]piperidine-1-carboxylic acid tert-butyl ester, or a pharmaceutically acceptable salt thereof.

### Claim 10

The compound:
(R)-2-Ethoxy-propan-1-ol.

### Claim 11 (depends on 1)

The method of treatment or prevention of high blood pressure, heart failure, glaucoma, myocardial infarction, renal failure, diabetic nephropathy and restenoses, comprising administering to a subject a therapeutically effective amount of a compound according to claim 1 or a pharmaceutically acceptable salt thereof.

### Claim 12 (depends on 1)

A pharmaceutical composition comprising a compound according to claim 1 and optionally one or more agents having cardiovascular activity.
